• Oric Pharmaceuticals posted a Q2 net loss of USD 41.49 million, widening from USD 36.36 million a year earlier.
• Operating loss widened to USD 45.3 million as R&D expenses rose 18.7% to USD 36.3 million.
• Cash, cash equivalents and investments totaled USD 387.6 million at June 30, with runway expected into 2H 2028.
• Initiated the Himalayas-1 global Phase 3 trial of rinzimetostat plus darolutamide in mCRPC; Bayer will supply darolutamide at no cost.
• Jacob M. Chacko said the Phase 3 start brings ORIC closer to a “potentially practice-changing therapy” for prostate cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608031605PRIMZONEFULLFEED9802687) on August 03, 2026, and is solely responsible for the information contained therein.